Influvak, 0.5 ml/dose 0.5 ml suspension

Influvac – forming development of specific immunity.

Pharmacodynamics

Forms specific immunity to influenza viruses of types A and B, which usually comes 14 days after vaccination and lasts up to 1 year.

Indications

Influenza prophylaxis in adults and children from 6 months of age.

Vaccination is recommended for all people and, above all, the following categories of the population at higher risk if influenza is combined with existing diseases/conditions:

• People over 65 years of age regardless of their health status;
• People with respiratory disease;
• People with cardiovascular disease of any etiology;
• Chronic renal failure
• Physicians with diabetes
• Physicians with immunodeficiency diseases (HIV infection, malignant blood diseases, etc.).
• and patients treated with immunosuppressants, cytostatics, radiation therapy or high doses of corticosteroids.Children and adolescents (6 months to 18 years of age) who receive long term medications containing acetylsalicylic acid and therefore are at increased risk of Reye’s syndrome due to influenza infection;
• Pregnant women (II-III trimester). Pregnant women belonging to high-risk categories should be vaccinated regardless of the stage of pregnancy.

Composition

Active substances:

Hemagglutinin (HA);

Neuraminidase (NA);

Associates:

Potassium chloride;

Potassium dihydrophosphate;

Sodium phosphate dihydrate;

sodium chloride;

calcium chloride dihydrate;

magnesium chloride hexahydrate;

water for injection

How to take, the dosage

Intramuscularly or subcutaneously (deep).

It is strictly prohibited to administer the drug intravenously. Immunization is carried out annually in the fall.

Adults and adolescents (from 14 years of age) – 0.5 ml once, children: from 6 months to 3 years – 0.25 ml, from 3 to 14 years – 0.5 ml once;

children who have not previously had influenza and not vaccinated, as well as patients with immunodeficiency – twice with an interval of 4 weeks.

Interaction

Influvavac® can be used at the same time as other vaccines (vaccines should be injected into different parts of the body with different syringes). There may be increased side effects.

If the patient is on immunosuppressive therapy, the immune response may be reduced.

False-positive serology tests (enzyme immunoassay (ELISA) tests) may occur after vaccination due to the production of IgM after vaccination.

Special Instructions

The vaccine has a shelf life of 12 months.

The expiration date is June 30 of the year following the year of manufacture.

Do not use after the expiration date printed on the package.

Contraindications

• hypersensitivity to chicken protein or any other component of the vaccine;
• high fever or allergic reactions after previous vaccination with subunit influenza vaccines.
• Vaccination is delayed until the end of acute manifestations of the disease and exacerbation of chronic diseases. For non-serious acute respiratory infections, acute intestinal and other illnesses, the vaccination is given as soon as the temperature returns to normal.

Side effects

Blood and lymphatic system disorders: rare – thrombocytopenia.

The immune system: rare – possible allergic reactions; very rare – anaphylactic shock.

Nervous system: often – headache; rarely – paresthesias, seizures, encephalomyelitis, neuritis, Guillain-Barré syndrome.

But no conclusive data on the association of these reactions with vaccination have been established.

Vascular system disorders: very rare – vasculitis with transient renal dysfunction.

General disorders: often – fatigue and neuralgia that do not require treatment and pass in 1-2 days.

Local reactions: redness, swelling, soreness, thickening, ecchymosis.

Systemic reactions: increase in body temperature, malaise, shivering, sweating, pain in muscles and joints.

.